Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 358 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Group D Placebo Comparator Clear all
Completed Phase 3 Interventional

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

NCT00067561
View directory record Official record
Conditions
Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions
Alosetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
177
States / cities
Birmingham, Alabama • Calera, Alabama • Tuscaloosa, Alabama + 149 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 1, 2026, 10:46 PM EDT
Active, not recruiting Not applicable Interventional

Myo-Inositol for Infertility in PCOS

NCT04407754
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Inositol supplement, Placebo supplement
Dietary Supplement
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 36 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 3 Interventional

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

NCT00199407
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

NCT00347555
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dental Pain Study of Analgesics in Patients Undergoing Molar Removal

NCT03652818
View directory record Official record
Conditions
Dental Pain
Interventions
Pre-Op pregabalin, Pre-Op Placebo 1, Post-Op pregabalin, Post-Op Placebo 1, Post-Op Placebo 2, Post-Op acetaminophen
Drug
Lead sponsor
Nevakar, Inc.
Industry
Eligibility
17 Years to 55 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Lonafarnib for Chronic Hepatitis D

NCT01495585
View directory record Official record
Conditions
Hepatitis D
Interventions
Lonafarnib, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968825
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

NCT02078674
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 64 Years
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
5
States / cities
Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults

NCT03562468
View directory record Official record
Conditions
Cognitive Function, Mood, Sleep
Interventions
300 mg/day of TRU NIAGEN (nicotinamide riboside), 1000 mg/day of TRU NIAGEN (nicotinamide riboside), Placebo
Dietary Supplement
Lead sponsor
ChromaDex, Inc.
Industry
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 1, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

NCT01679951
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 2 Interventional

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

NCT01046422
View directory record Official record
Conditions
Diabetes Type 2
Interventions
BMS-770767, Placebo, Metformin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Lomita, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 1, 2026, 10:46 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

NCT06579300
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-1088, Placebo for ABBV-1088, Itraconazole (ITZ)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT00394173
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions
DNK333, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Timeline
2006 – 2007
U.S. locations
37
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

NCT00556439
View directory record Official record
Conditions
Takayasu's Arteritis, Giant Cell Arteritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
15 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
8
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Nasal Protollin in Early Symptomatic Alzheimer's Disease

NCT07187141
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
Protollin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

NCT04223349
View directory record Official record
Conditions
Healthy
Interventions
JNJ-70033093, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of Vitamin D Statues on Endothelial Function

NCT01049048
View directory record Official record
Conditions
Cardiovascular Diseases, Vitamin D Deficiency
Interventions
Vitamin D3, Placebo
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 65 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

NCT03281876
View directory record Official record
Conditions
Respiratory Disorders
Interventions
NTHi Mcat investigational vaccine (GSK3277511A), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Mesa, Arizona • Phoenix, Arizona • Palm Springs, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

NCT00550043
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
INCB018424, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Huntsville, Alabama • Upland, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

NCT06774313
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-142, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03251482
View directory record Official record
Conditions
VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
Interventions
JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg, JNJ-64179375 (Dose to be Determined), JNJ-64179375 A mg/kg, JNJ-64179375 B mg/kg, JNJ-64179375 C mg/kg, JNJ-64179375 D mg/kg, Placebo JNJ-64179375, Apixaban placebo, Apixaban 2.5 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Pramipexole as a Treatment for Cocaine Dependence

NCT01651377
View directory record Official record
Conditions
Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

NCT01106677
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
45
States / cities
Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 1, 2026, 10:46 PM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)

NCT06404112
View directory record Official record
Conditions
Long COVID, Long COVID-19, Sleep Disturbance
Interventions
Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 1, 2026, 10:46 PM EDT